AllDocs -> cancers

Non-Small Cell Lung Stage I Stage II Stage III Stage IV T1- T2 T3 T4 N1 N2- N3 M0- M1- Tumor s 3 cm or less in greatest dimension, surrounded by lung or visceral plura without bronchoscopic evvidence of invatsion more proximal than the lobar bronchus - Tumor that is >3cm in greatest dimension, involves the mainstem bronchus > 2cm distal to the carina, invades the visceral pleura, or is associated with atelectasis or obstructive pneumonitis that extends to the hilar region but not the entire lung - Tumor of any size that directly invades any of the following the chest wall , diaphragm , mediastinum pleura, parietal pericardium, or tumor involving a main bronchus less than 2cm distal to the tracheal carina but not involving the carina or associated atelectasis or obstructive pneumonitis of the entire lung - Tumor of ...

BMC Cancer (2001) 1:5 http://www.biomedcentral.com/1471-2407/1/5 BMC Cancer (2001) 1:5 Research article Prophylactic cranial irradiation in small cell lung cancer : a systematic review of the literature with meta-analysis Anne-Pascale Meert 1 , Marianne Paesmans 1 , Thierry Berghmans 1 , Benoît Martin 1 , Céline Mascaux 1 , Frédéric Vallot 1 , Jean-Marc Verdebout 3 , Jean-Jacques Lafitte 2 and Jean-Paul Sculier* 1 Address: 1 Service de Médecine, Institut Jules Bordet, Bruxelles, Belgique, 2 Service de Pneumologie et d'Oncologie Thoracique, CHU Calmette, Lille, France and 3 Service d'Anatomo-Pathologie, Institut Jules Bordet, Bruxelles, Belgique E-mail: Anne-Pascale Meert ...

RNA binding proteins in lung cancer Luis M. Montuenga, Ph.D. Center of Applied Medical Research and Department of Histology and Pathology. School of Medicine. University of Navarra. Pamplona. Spain. Lung cancer is usually diagnosed in an advanced stage, too late for surgical intervention, and has, therefore, a high fatality rate. As early stage lung cancer has shown to have high cure rates, early detection should lead to improved survival and decreased mortality. A detailed characterization of the molecular mechanisms involved in lung carcinogenesis is a requirement to establish a “molecular signature” of lung cancer that will allow the development of biomarker-based early detection protocols. The overall goal of our project is to identify and validate new biomarkers for the early detection and by the biological profiling of early lung neoplastic or preneoplastic lesions ...

RNA-BINDING PROTEINS IN LUNG CANCER Luis M. Montuenga, Ph.D. University of Navarra, Spain Modeling Human Lung Cancer in mice 4th International Mouse Lung Tumorigenesis symposium Bar Harbor, October 23-26 2003 Page 2 Pre mRNA mRNA Protein Splicing and maturation genes mRNA transport and stability genes Translation control genes Posttranslational modification and protein degradation genes Changes in Gene Expression Modified from: Cell, 100, 57–70, 2000 The Hallmarks of Cancer Douglas Hanahan and Robert A. Weinberg Page 3 Dreyfuss et al. Nature Reviews Mol Cell 3: 195; 2002 hnRNPs EJC: Exon-Exon Junction Complex Poly A binding complex PABP Etc. RNA-BINDING PROTEINS ...

2003 SPUH Cancer Center Annual Report 10 asdasDasdasdsadasdSczxv analytic cancers between 1992 and 2002; cases in which patients were either diagnosed or initially treated at SPUH. 65% (591) were NSCLC and 59% of those were either stage III or IV at time of diagnosis. The most common histologic type was adenocarcinoma. Our patient population at SPUH indicates that we have seen primarily Caucasian men who are at least 60 years of age and present with late stage disease. The distribution by age illustrated in Figure 1 shows that the decade at time of diagnosis has shifted. In 2002 we diagnosed more patients between 50-59 years of age compared to 1997. A lso of note is that more women were diagnosed in 2002 within that age group as well. This may be due to improved imaging capabilities and the fact that women are more likely to have routine visits with their ...

Mortality from Lung cancer in NORWAY, 1952-95 (annual rates per 100 000) Year Male 35-54 Female 35-54Male 55-74 Female 55-74 1952-3 9.5 1.6 37.3 15.1 1954-5 11.3 1.6 40.1 13.8 1956-7 8.5 2.1 48.6 13.2 1958-9 9.3 1.8 61.9 14.7 1960-1 11.2 2 72.3 14.3 1962-3 10.1 2.7 76.5 12.8 1964-5 13.2 2.6 82.3 11.7 1966-7 13.1 2.9 90.2 15.1 1968-9 14.3 4.2 108 18.4 1970-1 14.4 4.3 118 17.3 1972-3 14.1 5.4 119.4 19.4 1974-5 15.7 4.9 129 20.3 1976-7 17.5 5.2 139.3 25.5 1978-9 16.6 5.8 145.7 23.5 1980-1 17.3 6.6 162.7 29.6 1982-3 19.5 7.8 160.7 33.2 1984-5 ...

Web Immagini Gruppi Directory News Novità! Ricerca avanzata Preferenze Cerca nel Web Cerca solo le pagine in Inglese Spiacenti, nessun contenuto associato a questo URL Web La ricerca di - cache:n7F1SAdt9OgJ:www.bccancer.bc.ca/NR/rdonlyres/eky33lkazqrmk4nkn2jkzsqrq3nup7xqulj2b724bce27hywcvkzfnzniukj4pkpqb2h3yliti3jcf/SMithaninov2003.ppt allintitle: lung cancer filetype:pdf OR filetype:doc OR filetype:ppt OR filetype:xls OR filetype:rtf - non ha prodotto risultati in nessun documento. Suggerimenti: - Assicurarsi che tutte le parole siano state digitate correttamente. - Provare con parole chiave diverse. - Provare con parole chiave più generiche. ...

The incidence of lung cancer in men is high but has decreased by 21% since 1989-91, and in women increased up to 1989-91 and has been stable since. Mortality from lung cancer followed similar trends reducing by 17% in men since 1980-82 and increasing by 46% in women between 1980-82 and 1989-91 and remaining stable since. Lung Cancer is the leading cause of cancer mortality amongst men and the second highest cause of cancer mortality amongst women in South Australia. Background notes Lung Cancer Page 2 Male Lung Cancer - Incidence and Mortality* 1977-2000 All Ages Source - SA Cancer Registry Data 0 10 20 30 40 50 60 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 Year ...

Lung Cancer Management Study Day Aim To enable participants to have a general understanding of lung cancer epidemiology, diagnosis and treatment, including the social and psychosocial management. Learning Outcomes By the end of the day course participants will have: • An understanding of the incidence, risks and trends of lung cancer disease • A basic understanding of the clinical manifestations, tumour types and diagnostic methods used in lung cancer disease • Raised awareness of surgical procedures used in the management of lung cancer • A basic understanding of chemotherapy and radiotherapy in the treatment of lung cancer • Gained insight into the lung cancer issues arising through client personal experience . • An improved understanding of the manifestation, identification ...

B.C. Cancer Agency Protocol Summary LUNAVP Page 1 of 1 TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH CISPLATIN AND VINORELBINE (INTERIM VERSION) Protocol Code: LUNAVP Tumour Group: Lung Contact Physician: Dr. Christopher Lee ELIGIBILITY: Advanced non-small cell lung cancer ECOG performance status of 0, 1 or 2 EXCLUSIONS: More than one previous chemotherapy regimen TESTS: Baseline: CBC & differential, platelets, creatinine, liver function tests, bilirubin Before each treatment: CBC and differential, platelets If clinically indicated: creatinine, bilirubin prior to each cycle PREMEDICATIONS: Antiemetic protocol for High Moderate emetogenic chemotherapy protocols as long as cisplatin dose is not = 50 mg. If cisplatin is = 50 mg use antiemetic protocol for Highly emetogenic ...

R A D I A T I O N T H E R A P Y f o r LUNG CANCER Facts to Help Patients Understand Their Treatment ABOUT ASTRO The American Society for Therapeutic Radiology and Oncology is the largest radiation oncology society in the world. ASTRO's mission is to advance radiation oncology by promoting excellence in patient care, supporting research and distributing research results. LEARNING ABOUT CLINICAL TRIALS The radiation oncology team is always looking for new ways to treat and cure cancer through studies called clinical trials. Today's lung cancer radiation therapy treatments are the result of clinical trials completed in the past proving that radiation therapy kills cancer cells and is safe long term. For more information on clinical trials, please visit the following Web sites: National Cancer Institute ...

4 JUNE 2004 VOL 304 SCIENCE www.sciencemag.org 1458 Although a covalent bond is much stronger, precursors, acidic/basic conditions, and high temperatures are required for chemi- cal synthesis. For MSAs, synthetic chem- istry is used only to construct the basic building blocks (that is, the molecules), and weaker intermolecular bonds are in- volved in arranging and binding the blocks together into a structure. This weak bond- ing makes solution, and hence reversible, processing of MSAs possible. The current top-down approach to nan- otechnology, whereby nanostructures are created, manipulated, and modified by ma- chine, is incapable of offering the complex- ity and economy of scale that MSA demon- strates in nature. Thus, solution processing and manufacturing of MSAs offer the envi- able goal of mass production with the pos- sibility of error correction ...

Lung Cancer Lung cancer progresses rapidly. The median survival time after diagnosis is less than four months, and about 80% of patients die within one year. Symptoms Symptoms may include cough (which may bring up blood), chest pain, breathlessness and continuous hoarseness of voice. One may also find tiredness, loss of appetite, weight loss, and repeated chest infections. The tumour may not show any early signs, with the first indications being due to the effects of cancer that has spread to other parts of the body. The most common sites of lung cancer metastases are the brain, liver and bones. Types of lung cancer Lung cancer is split into two main categories: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). The most common is NSCLC, which accounts for approximately ...

ROYAL COLLEGE OF PHYSICIANS The National LUng CAncer DAta Audit Project (LUCADA) DOCUMENT CATALOG Version: DRAFT V0.1 Date: January 2004 Page 2 LUCADA Lung Cancer Audit Table of Contents Date: 30/06/2004 Page 2 of 147 Table of Contents Data Set Version 1.2 3 Data Manual Version 1.2 ..6 LUCADA Application Manual..6 CSV Upload/Download File Specification..6 XML Upload/ Download File Specification6 LUCADA System Validation Rules 6 Caldicott Guardian Advice ..6 Open Exeter logon forms - Data User Certification 6 Page 3 LUCADA Lung Cancer Audit Dataset Date: November 2003 Version No.: 1.2 Page 3 of 147 Data Set Version 1.2 LUCADA Data set v1.2 – based on NCDS V4.0 Please note that the ‘data ...

Platinum-containing chemotherapy has been commonly used as standard therapy for small cell lung cancer (SCLC). However, platinum causes renal dysfunction. 1,2 We report a SCLC patient with paraneoplastic nephrotic syndrome who was successfully treated with platinum-containing chemotherapy. A com- plete tumour response could be achieved; however, his proteinuria did not decrease and renal function got worse every time he re- ceived the chemotherapy. A 74-year-old male was admitted to our hospital with the oedema of the lower ex- tremities that developed during the last three months. On physical examination, oedema was still present. Laboratory results were as follows: haemoglobin 10.6 g/dl, potassium 4.3 mEq/l, serum creatinine 1.0 mg/dl, blood urea nitrogen 34.2 mg/dl. Creatinine clear- ance was 43.0 ml/min and the urine sediment was free of casts and ...

Clinical Effectiveness & Evaluation Unit Chair of Network Lung Cancer Site Specific Group Cc: Network Medical Directors/Lead Clinicians Network Lead Managers March 2004 LUCADA, LUng CAncer DAta: National Clinical Audit Dear Important: Call for Participants The LUCADA Team is now calling for expressions of interest from NHS organisations in England, for participation in the next phase of the LUCADA clinical audit programme. This phase will begin in June 2004 and we will be offering all those who wish to participate the opportunity to do so by December 2004. LUCADA is commissioned by the Commission for Health Audit and Improvement (CHAI) from April 2004 as part of the National Clinical Audit Support Programme being managed by the NHS Information Authority. We are aiming to produce national, comparative, risk-adjusted clinical ...

ROYAL COLLEGE OF PHYSICIANS The National LUng CAncer DAta Audit Project (LUCADA) PROPOSED DATA MANUAL TO SUPPORT ‘FIRST PRIORITY’ AUDIT OUTPUTS Title : Data Manual Version: V1.2 Date: November 2003 Page 2 Introduction The manual is designed to compliment the Intercollegiate Lung Cancer Group proposed dataset for the LUCADA project. The purpose of the dataset is to support the first priority audit outputs and was agreed by the group during the period September 2001 to May 2002. The manual examines each element of the proposed dataset. It details the content of each data item, including its definition and purpose, and guidelines for collection. The content of the manual is extracted from the more comprehensive Lung Cancer Data Manual, designed to support the full National Cancer Dataset. Each data item listed ...

1 ROYAL COLLEGE OF PHYSICIANS The National LUng CAncer DAtaset Audit Project (LUCADA) Title: User Acceptance Test Report (CSV Uploading) Version: Final V1.0 Date: February 2003 Author: Margaret Vartanian Page 2 2 Contents Section Page 1 Executive Summary 3 2 Background 4 3 Aim of User Acceptance Testing 4 4 Methodology 5 5 Details of the test 5 5.1 Agreed Actions from the Last Testing Round 6 5.2 CSV upload 6 6 Support 9 6.1 Categorising the Calls 10 6.2 IT Issues and Problems 11 7 Conclusions 13 Appendix A – Security and Confidentiality 14 Page 3 3 1. Executive Summary ...

ROYAL COLLEGE OF PHYSICIANS The National LUng CAncer DAta Audit Project (LUCADA) Title: Caldicott Guardian Advice Version: Draft V0.3 Date: Nov 2003 Author: Steve Wise/Margaret Vartanian Page 2 Change Log Version Date Issued Brief Summary of Change Author’s Name Draft 0.1 Oct 2003 First draft Steve Wise/Margaret Vartanian Draft 0.2 Nov 2003 Addition of audit trail tool info Steve Wise/Margaret Vartanian Draft 0.3 Nov 2003 revise patient leaflet reference Steve Wise Final 1.0 Final 1.1 (revised) Final 2.0 Page 3 The LUCADA project ( LUng CAncer DAta National Audit) is a national comparative clinical audit of lung cancer treatment and management. This programme is being run jointly by the Royal College of ...

USER ACCEPTANCE TEST (UAT) REPORT In association with the NHSIA LUCADA ( Lung Cancer Data) National Audit Project User Acceptance Test Report Final V1.0 November 2003 Margaret Vartanian Page 2 LUCADA User Acceptance Test Report Version No: Final 1.0 Date November 2003 Page 2 of 16 Contents Section Page 1 Executive Summary 3 2 Background 4 3 Aim of User Acceptance Testing 4 4 Methodology 4 5 Details of the test 5 5.1 Access to the System 5 5.2 Data entry and CSV upload 7 6 Conclusions 13 Appendix A – Security and Confidentiality 14 Appendix B – Discussions with Users 16 Page 3 LUCADA User Acceptance ...

Please note that the patient details shown in this document are fictitious and do not relate to a real person. They are displayed as an example. 1 ROYAL COLLEGE OF PHYSICIANS The National LUng CAncer DAtaset Audit Project (LUCADA) Title: Application Manual Version: Final V1.0 Date: November 2003 Author: Steve Wise/Margaret Vartanian Page 2 Please note that the patient details shown in this document are fictitious and do not relate to a real person. They are displayed as an example. 2 Change Log Version Date Issued Brief Summary of Change Author’s Name Final 1.0 Nov 2003 Amended to reflect system changes Margaret Vartanian Final 1.1 (revised) Final 2.0 Page 3 Please note that the patient details shown in this ...

IJTCVS Cankurtaran et al 91 2004; 20: 91–92 Mediastinoscopy received a nine month course of anti-tuberculosis treatment postoperatively. He had presented again with a paratracheal mass on the left side 5 years after his initial operation. Bronchoscopy and transbronchial Fine Needle Aspiration (FNA) had not shown any malignancy. Radiological findings had been very suspicious of recurrent disease, therefore a redo CM had been performed for diagnostic purposes. Histology had revealed a recurrent disease in the mediastinum and the patient had been given 6 cycles of chemotherapy resulting in a complete response. On one of his routine follow-up visits, repeated Computed Tomographic (CT) scan of his chest once again revealed an enlarging mass in the left paratracheal region 2 years after the chemotherapy. Fiberoptic bronchoscopy failed to show an endobronchial lesion, however ...

Corporate Medical Policy Lung Cancer Screening, CT Scanning File Name: lung_cancer_screening_ct_scanning Policy Number: RAD5095 Origination: 10/2001 Last Review: 9/2002 Next Review: 9/2004 Description of Procedure or Service There has been longstanding research interest in developing screening techniques for patients at high risk for lung cancer . Previous studies of serial sputum samples or chest x-rays failed to demonstrate that screening improved health outcomes. Recently, there has been interest in CT scanning as a screening technique, using either spiral (also referred to as helical) or electron beam (also referred to as ultrafast) CT scanning. Com- pared to conventional CT scanning, these CT scans allow for continuous images and shorten the scan time and radiation exposure. For example, a complete CT scan can be obtained within 20 seconds ...

1 INTERCOLLEGIATE LUNG CANCER GROUP IN COLLABORATION WITH THE CLINICAL EFFECTIVENESS AND EVALUATION UNIT OF THE ROYAL COLLEGE OF PHYSICIANS OF LONDON DEPARTMENT OF HEALTH NHS INFORMATION AUTHORITY TRENT CANCER REGISTRY OUTLINE PROPOSAL FOR A SYSTEM FOR THE NATIONAL COLLECTION, COLLATION, ANALYSIS AND REPORTING OF ACTIVITY, PERFORMANCE AND OUTCOME DATA IN LUNG CANCER (The LUng CAncer DAta – LUCADA – Project) Version 1 – 6th March 2002 Dr Michael Peake, Chair of Inter Collegiate Lung Cancer Group Dr Michael Pearson, Director of RCP CEEu Nancy Wolstenholme, Programme Manager NCASP Jane Ingham, Manager RCP CEEu _ Pre amble Lung Cancer is the commonest cause of death from cancer in the Western world. The number of deaths exceeds that from breast, colo-rectal and prostate ...

B R E A S T C A N C E R C A R E K I L N H O U S E , 2 1 0 N E W K I N G S R O A D , L O N D O N S W 6 4 N Z . T E L : 0 2 0 7 3 8 4 2 9 8 4 H E L P L I N E 0 8 0 8 8 0 0 6 0 0 0 W E B S I T E W W W . B R E A S T C A N C E R C A R E . O R G . U K R E G I S T E R E D I N E N G L A N D C O M P A N Y N O . 2 4 4 7 1 8 2 . R E G I S T E R E D C H A R I T Y N O . 1 0 1 7 6 5 8 Secondary lung cancer September 2001 This factsheet is for those who have been diagnosed with secondary cancer in the lungs that has spread from the breast. It describes what secondary lung cancer is, what the symptoms are and the treatments used. We hope it answers some of your questions and helps you to discuss your options with your specialist team. What is secondary lung cancer ? Secondary lung cancer occurs when cancer cells spread from the breast through the bloodstream ...

Secondary lung cancer This factsheet is for those who have been diagnosed with secondary cancer in the lungs that has spread from the breast. It describes what secondary lung cancer is, what the symptoms are and the treatments used. We hope it answers some of your questions and helps you to discuss your options with your specialist team. What is secondary lung cancer ? Secondary lung cancer occurs when cancer cells spread from the breast through the bloodstream and settle in the lungs. You may hear this type of spread described as metastases, recurrence of the cancer , secondary tumours or secondaries. The cells in the lungs are breast cancer cells. It is not the same as having a cancer that starts in the lungs (primary lung cancer ). How do the lungs work? To understand some of the symptoms described in this factsheet ...

7 Lung Cancer Cancer of the lung and bronchus is the second most common cancer among both men and women and is the leading cause of cancer death in both sexes. There were an estimated 164,100 new cases of lung cancer and an estimated 156,900 deaths from lung cancer in the United States in 2000. Among all cancer deaths in the State and the County, it has been the leading causes of death for many years. In 2001, it caused 119 deaths out of 1681 deaths in Lancaster County. Smoking is the single most well established attributable risk factor for lung cancer . Other risk factors include exposure to secondhand tobacco smoke, occupational exposure, and indoor and outdoor air pollution. The higher the number of cigarettes smoked per day the higher the risk of dying from lung cancer . However, cessation of smoking decreases the risk of having lung ...

6 C L E V E L A N D C L I N I C T A U S S I G C A N C E R C E N T E R T HE C LEVELAND C LINIC T AUSSIG C ANCER C ENTER is participating in an international, pivotal Phase III clinical study combining Xcytrin (motexafin gadolinium) and whole brain radiation therapy (WBRT) for non-small cell lung cancer patients with brain metastases. Clinic radiation oncologist John Suh, M.D., is an investigator for this multinational trial. “The SMART trial is designed to assess the impact of whole brain radiation therapy on neuro- cognitive function. Although the main goal is to achieve extended control in brain metastases patients, quality of life issues need to ...

lung cancer Surgical principles of lung cancer treatment Abdel Rahman M.Abdel Rahman, MD.** *Department of cardiothoracic surgery , Emory University school of medicine , Atlanta , Georgia . **Department of surgery ,National Cancer institute Cairo University. Kamal A. Mansour , MD. * By Lung cancer remains the most common cause of death by malignancy in both men and women. Despite the advances in the understanding of the molecule biology of pulmonary malignancy , surgical resection offers the best opportunity for cure of non-small cell lung cancer . Introduction Preoperative assessment It’s now standard practice to carefully stage all cancers of the lung at the time of their initial diagnosis. Since 1986 , the international tumor node ...

Web Immagini Gruppi Directory News Novità! Ricerca avanzata Preferenze Cerca nel Web Cerca solo le pagine in Inglese Spiacenti, nessun contenuto associato a questo URL Web La ricerca di - cache:tryI3fkxnSEJ:ejm.yyu.edu.tr/2000-2/48.pdf allintitle: lung cancer filetype:pdf OR filetype:doc OR filetype:ppt OR filetype:xls OR filetype:rtf - non ha prodotto risultati in nessun documento. Suggerimenti: - Assicurarsi che tutte le parole siano state digitate correttamente. - Provare con parole chiave diverse. - Provare con parole chiave più generiche. - Provare con un numero minore di parole chiave. ...